These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 26805015)

  • 1. Nonalcoholic fatty future disease.
    Polyzos SA; Mantzoros CS
    Metabolism; 2016 Aug; 65(8):1007-16. PubMed ID: 26805015
    [No Abstract]   [Full Text] [Related]  

  • 2. Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): prevalence, therapeutic innovations, and stumbling blocks for clinical development.
    Alkhouri N
    Expert Opin Investig Drugs; 2020 Feb; 29(2):115-116. PubMed ID: 31971024
    [No Abstract]   [Full Text] [Related]  

  • 3. Nonalcoholic Fatty Liver Disease.
    Gaglio PJ
    Clin Liver Dis; 2016 May; 20(2):xiii-xiv. PubMed ID: 27063278
    [No Abstract]   [Full Text] [Related]  

  • 4. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Fukusato T
    World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Similarities and differences between pediatric and adult nonalcoholic fatty liver disease.
    Crespo M; Lappe S; Feldstein AE; Alkhouri N
    Metabolism; 2016 Aug; 65(8):1161-71. PubMed ID: 26961580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A non-invasive prediction model for non-alcoholic steatohepatitis in paediatric patients with non-alcoholic fatty liver disease.
    Eng K; Lopez R; Liccardo D; Nobili V; Alkhouri N
    Dig Liver Dis; 2014 Nov; 46(11):1008-13. PubMed ID: 25106814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. World Gastroenterology Organisation global guidelines: Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    ; LaBrecque DR; Abbas Z; Anania F; Ferenci P; Khan AG; Goh KL; Hamid SS; Isakov V; Lizarzabal M; Peñaranda MM; Ramos JF; Sarin S; Stimac D; Thomson AB; Umar M; Krabshuis J; LeMair A;
    J Clin Gastroenterol; 2014 Jul; 48(6):467-73. PubMed ID: 24921212
    [No Abstract]   [Full Text] [Related]  

  • 8. Liver histology and clinical trials for nonalcoholic steatohepatitis-perspectives from 2 pathologists.
    Kleiner DE; Bedossa P
    Gastroenterology; 2015 Nov; 149(6):1305-8. PubMed ID: 26409177
    [No Abstract]   [Full Text] [Related]  

  • 9. Baseline Parameters in Clinical Trials for Nonalcoholic Steatohepatitis: Recommendations From the Liver Forum.
    Patel YA; Imperial JC; Muir AJ; Anstee QM; DeBrota D; Dimick-Santos L; Filozof C; Mehta R; Sanyal AJ; Schabel E; Neuschwander-Tetri BA; Miller V;
    Gastroenterology; 2017 Sep; 153(3):621-625.e7. PubMed ID: 28757264
    [No Abstract]   [Full Text] [Related]  

  • 10. Nonobese Fatty Liver Disease.
    Kim D; Kim WR
    Clin Gastroenterol Hepatol; 2017 Apr; 15(4):474-485. PubMed ID: 27581063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Controlled attenuation parameter for the detection and quantification of hepatic steatosis in nonalcoholic fatty liver disease.
    Chan WK; Nik Mustapha NR; Mahadeva S
    J Gastroenterol Hepatol; 2014; 29(7):1470-6. PubMed ID: 24548002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonalcoholic fatty liver disease and hepatic cirrhosis: Comparison with viral hepatitis-associated steatosis.
    Haga Y; Kanda T; Sasaki R; Nakamura M; Nakamoto S; Yokosuka O
    World J Gastroenterol; 2015 Dec; 21(46):12989-95. PubMed ID: 26675364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Guidelines of prevention and treatment of nonalcoholic fatty liver disease (2018, China).
    Fan JG; Wei L; Zhuang H;
    J Dig Dis; 2019 Apr; 20(4):163-173. PubMed ID: 30444584
    [No Abstract]   [Full Text] [Related]  

  • 14. Structure of proof of concept studies that precede a nonalcoholic steatohepatitis development program.
    Williams RN; Filozof C; Goldstein BJ; Cusi K
    Clin Pharmacol Ther; 2017 Apr; 101(4):444-446. PubMed ID: 28032901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progress and challenges in the prevention and control of nonalcoholic fatty liver disease.
    Cai J; Zhang XJ; Li H
    Med Res Rev; 2019 Jan; 39(1):328-348. PubMed ID: 29846945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Genetics of Nonalcoholic Fatty Liver Disease: Spotlight on PNPLA3 and TM6SF2.
    Anstee QM; Day CP
    Semin Liver Dis; 2015 Aug; 35(3):270-90. PubMed ID: 26378644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonalcoholic fatty liver disease as a multi-systemic disease.
    Fotbolcu H; Zorlu E
    World J Gastroenterol; 2016 Apr; 22(16):4079-90. PubMed ID: 27122660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Attribution of Nonalcoholic Steatohepatitis as an Etiology of Cirrhosis for Clinical Trials Eligibility: Recommendations From the Multi-stakeholder Liver Forum.
    Noureddin M; Chan JL; Barradas K; Dimick-Santos L; Schabel E; Omokaro SO; Anania FA; Myers RP; Miller V; Sanyal AJ; Chalasani N;
    Gastroenterology; 2020 Aug; 159(2):422-427.e1. PubMed ID: 32353369
    [No Abstract]   [Full Text] [Related]  

  • 19. In vivo (1)H-MRS hepatic lipid profiling in nonalcoholic fatty liver disease: an animal study at 9.4 T.
    Lee Y; Jee HJ; Noh H; Kang GH; Park J; Cho J; Cho JH; Ahn S; Lee C; Kim OH; Oh BC; Kim H
    Magn Reson Med; 2013 Sep; 70(3):620-9. PubMed ID: 23023916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidemiology and Natural History of Nonalcoholic Fatty Liver Disease.
    Satapathy SK; Sanyal AJ
    Semin Liver Dis; 2015 Aug; 35(3):221-35. PubMed ID: 26378640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.